Previous 10 | Next 10 |
Rocket Pharmaceuticals press release ( NASDAQ: RCKT ): Q4 GAAP EPS of -$0.92 misses by $0.10 . Cash, cash equivalents and investments of approximately $400M; expected operational runway through 2024 For further details see: Rocket Pharmaceuticals GAAP EPS of -$0.92 m...
Advanced pipeline of four clinical programs across AAV cardiology and LV hematology portfolios delivering strong results for Danon Disease, Fanconi Anemia, LAD-I and PKD Expanded leadership position in AAV cardiac gene therapy, with significant opportunities for value creation across Dano...
Summary Rocket Pharmaceuticals stock trades at ~$19.5 today - back in December 2021 it had hit highs of >$60. The highs were achieved when Rocket's in vivo gene therapy showed promise treating patients with a rare genetic heart condition known as Danon Disease. The FDA placed a c...
Summary Rocket Pharmaceuticals, Inc. performed beautifully for me in the last half year. They have a number of catalysts in the next few months. Rocket has strong upside from here. I covered Rocket Pharmaceuticals, Inc. ( RCKT ) 6 months ago, and also took a position. ...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to participate in ...
The U.S. Food and Drug Administration (FDA) granted regenerative medicine advanced therapy (RMAT) designation to Rocket Pharmaceuticals' ( NASDAQ: RCKT ) gene therapy RP-A501 to treat Danon Disease. Danon disease is a rare genetic disorder characterized by weakening of the heart ...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medici...
The following slide deck was published by Rocket Pharmaceuticals, Inc. in conjunction with this event. For further details see: Rocket Pharmaceuticals (RCKT) Presents At 41st Annual Healthcare Conference - Slideshow
RP-A601 for Arrhythmogenic Cardiomyopathy due to PKP2 pathogenic variants (PKP2-ACM) represents meaningful commercial opportunity with estimated prevalence of 50,000 adults and children in the U.S. and EU; IND filing anticipated in Q2 2023 In support of Phase 2 pivotal study, latest posit...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to prese...
News, Short Squeeze, Breakout and More Instantly...
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a le...
2024-06-02 14:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...